Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
490 Results for "
TNF activity
" in MedChemExpress (MCE) Product Catalog:
Products (490)
490 Results for "TNF activity" in MCE Product Catalog:
Cat. No.: HY-159520
CAS No.: 2731294-23-6
Synonyms: Ofirnoflast; HT-6184
Research Areas:
Ofirnoflastum (Ofirnoflast) is an orally active first-in-class allosteric NEK7 inhibitor with an IC50 of 46 nM. Ofirnoflastum binds an allosteric site adjacent to NEK7’s ATP-binding pocket, induces conformational shifts, disrupts NEK7-NLRP3 binding, blocks NLRP3 inflammasome assembly, spares NEK7’s physiological functions, and suppresses caspase-1, caspase-8, NF-κB, and TNF activity. Ofirnoflastum reduces pro-inflammatory cytokine production, suppresses ASC specks, IL-1β release, pyroptotic cell death, and leukemic burden, induces apoptosis and erythroid differentiation, restores hematopoiesis, and improves outcomes in colitis models. Ofirnoflastum can be used for the research of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia .
Cat. No.: HY-167754
CAS No.: 1609382-32-2
Target:
Research Areas:
Resolvin D5 n-3 DPA is a Docosapentaenoic acid (DPA) derived specialized proresolving lipid mediator (SPM). Resolvin D5 n-3 DPA is a GPR101, GPR12, and GPR84 agonist with EC50s of 4.6 pM, 14 pM, and 1.5 pM, respectively. Resolvin D5 n-3 DPA possesses potent pro-resolution and anti-inflammatory actions. Resolvin D5 n-3 DPA reduces cell adhesion onto TNF-α-activated human endothelial monolayers. Resolvin D5 n-3 DPA displays potent leukocyte-directed activities, upregulating the ability of neutrophils and macrophages to phagocytose bacteria. Resolvin D5 n-3 DPA can be used for the study of intestinal inflammation .
Cat. No.: HY-16782R
CAS No.: 945614-12-0
Synonyms: ARRY-614 (Standard)
Pexmetinib (Standard) (ARRY-614 (Standard)) is the analytical standard of Pexmetinib (HY-16782). This product is intended for research and analytical applications. Pexmetinib (ARRY-614) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis .
Cat. No.: HY-171591
CAS No.: 2810810-00-3
Research Areas:
SIK2-IN-4 (Compound 4) is a highly selective SIK1/2 inhibitor (IC50s 0.143 and 0.076 μM, respectively). SIK2-IN-4 reduces the phosphorylation of transcription coactivator 3 (CRTC3) by targeting SIK1/2, thereby regulating cAMP response element binding protein (CREB)-dependent transcriptional activity. SIK2-IN-4 inhibits the production of pro-inflammatory cytokines such as TNF (IC50: 0.11 µM), IL-12/23 p40 (IC50: 0.25 µM), and IL-23 (IC50: 0.47 µM), while inducing the expression of the anti-inflammatory cytokine IL-10. SIK2-IN-4 can be used to study intestinal inflammation and other chronic inflammatory diseases .
Cat. No.: HY-180109
Synonyms: Benzo-17R-Resolvin D2
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Benzo-17R-RvD2 (Benzo-17R-Resolvin D2) is a benzo-containing analog of RvD2 (HY-121636). Benzo-17R-RvD2 enhances human macrophage efferocytosis, limits neutrophil infiltration, reduces TNF-α, and increases IL-1 receptor antagonist in peritonitis. Benzo-17R-RvD2 promotes E. coli killing by human leukocytes and reduces neutrophil swarm area without compromising anti-Candida activity. Benzo-17R-RvD2 activates the human-RvD2 receptor with an EC50 ∼1.5 nM. Benzo-17R-RvD2 can be used in research on inflammation-associated diseases such as cardiovascular disease, cancer, neuroinflammation, pain, and muscle regeneration .
Cat. No.: HY-181576
CAS No.: 3115784-59-0
Target:
Research Areas:
ROCK2-IN-14 is an orally active, selective ROCK2 inhibitor (IC50=4.8 nM) with 212-fold selectivity over ROCK1 (IC50=1.01 μM). By inhibiting the ROCK2/S100A9 signaling pathway, ROCK2-IN-14 downregulates S100A9 expression, inhibits NM2 phosphorylation and restores cytoskeletal abnormalities. Furthermore, ROCK2-IN-14 reduces inflammatory cytokine levels, alleviates skin inflammation and exerts anti-inflammatory activity. ROCK2-IN-14 also significantly inhibits ear thickening in a mouse model of atopic dermatitis (AD), and decreases the levels of IgE, TNF-α, IL-6 and TSLP. ROCK2-IN-14 can be used for research on atopic dermatitis .
Cat. No.: HY-187563
Target:
Research Areas:
RNP-11 is a selective COX-2 inhibitor with an IC50 of 42.85 μg/mL against human COX-2, and also acts as a bactericide and anti-inflammatory agent. RNP-11 inhibits the production of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β, disrupts bacterial cell membranes and induces bacterial cell death. RNP-11 exhibits activity against strains of Staphylococcus and Enterococcus, including Methicillin (HY-121544)-resistant Staphylococcus aureus and Vancomycin (HY-B0671)-resistant Enterococcus faecium. RNP-11 reduces the load of Staphylococcus aureus, exerting dual effects of pathogen clearance and inflammatory response alleviation in a mouse skin infection model,. RNP-11 can be used in research related to infections caused by Staphylococcus, Staphylococcus aureus and Enterococcus faecium .
Cat. No.: HY-P11617
Target:
Research Areas:
Cat. No.: HY-W010201S
CAS No.: 220687-53-6
Synonyms: (±)-Citronellol-d6; (±)-β-Citronellol-d6
Cat. No.: HY-W010201S1
Synonyms: (±)-Citronelloll-d3; (±)-β-Citronelloll-d3
Cat. No.: HY-N0278A
CAS No.: 90921-11-2
Synonyms: (Rac)-Pulsatilla camphor; (Rac)-Anemonine
Cat. No.: HY-N13817
CAS No.: 56682-25-8
Target:
Cat. No.: HY-148511
CAS No.: 147063-80-7
Synonyms: CMP-001
Research Areas:
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .
Cat. No.: HY-173485
Research Areas:
SARS-CoV-2 Mpro-IN-41 (Compound 7e) is an orally active inhibitor of COX-2 and SARS-CoV-2 M pro (IC50 values are 9.66 μM and 13.24 μM, respectively). SARS-CoV-2 Mpro-IN-41 also has a certain inhibitory activity against COX-1 (IC50: 46.11 μM). SARS-CoV-2 Mpro-IN-41 can significantly inhibit the expression of inflammatory-related cytokines (such as TNF-α, IL-6, IL-1β) and exert anti-inflammatory effects. SARS-CoV-2 Mpro-IN-41 exerts anti-inflammatory and antiviral effects by selectively inhibiting COX-2 and SARS-CoV-2 M pro. SARS-CoV-2 Mpro-IN-41 can be used for anti-inflammatory and anti-coronavirus research .
Cat. No.: HY-N16527
CAS No.: 233690-85-2
Cat. No.: HY-N2473R
CAS No.: 94367-42-7
Cat. No.: HY-N4267
CAS No.: 13060-14-5
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
